{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-014231","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.547957+00:00","generated_at":"2026-05-16T10:08:16.508049+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million","bullets":["Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.","Jaguar receives $18M upfront ($16M at closing + $2M on conditions) and up to $20M in milestone/future payments.","Jaguar retains manufacturing role; non-dilutive capital funds rare-disease pipeline (short bowel syndrome, MVID).","Jaguar has buy-back option after 5 years or upon FDA approval of additional crofelemer indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-014231","json":"https://secwatch.observer/filing/0001193125-26-014231.json","markdown":"https://secwatch.observer/filing/0001193125-26-014231.md","text":"https://secwatch.observer/filing/0001193125-26-014231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/0001193125-26-014231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/jagx-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:08:16.508049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19e328e861279156ecde7798ddc58737c3c2577b","claim":"Jaguar Health, Inc. entered into License Agreement with Woodward Specialty LLC and Future Pak, LLC valued at $18 million (effective 2026-01-12).","evidence_excerpt":"On January 12, 2026 (the “Effective Date”), Napo Pharmaceuticals, Inc. (“Napo”), a wholly-owned subsidiary of Jaguar Health, Inc., a Delaware corporation (the “Company”), and the Company, entered into a license agreement (the “License Agreement”) with Woodward Specialty LLC (the “Licensee”), an affiliate of Future Pak, LLC (“Future Pak”), and Future Pak","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/0001193125-26-014231-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Woodward Specialty LLC and Future Pak, LLC"},{"label":"Value","value":"$18 million"},{"label":"Effective","value":"2026-01-12"}]},{"claim_id":"a6e737307dc28a1a5a3cb685ef11936629042713","claim":"Jaguar Health, Inc. entered into Supply Agreement with Woodward Specialty LLC and Future Pak, LLC (effective 2026-01-12).","evidence_excerpt":"Also on the Effective Date, Napo, Licensee and Future Pak entered into a manufacturing and supply agreement (the “Supply Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526014231/0001193125-26-014231-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Woodward Specialty LLC and Future Pak, LLC"},{"label":"Effective","value":"2026-01-12"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}